Rating Change
Chardan Capital analysts initiated coverage on Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) with a rating of Buy on August 18, 2026.
new coverageNASDAQ:RANI
Chardan Capital Initiates Coverage on Rani Therapeutics Holdings, Inc. (RANI) with Buy
Chardan Capital analysts initiated coverage on Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) with a rating of Buy on August 18, 2026.
At publication ·
What changed
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) · new coverage
- Firm
- Chardan Capital
- Rating
- Buy
- Price at event
- $0.79
- Market capitalization
- $107.3M
At a glance
Key takeaways
- Chardan Capital initiated Buy coverage on Rani Therapeutics (RANI) on August 18, 2026, with the stock trading at $0.79 and a market capitalization of $107.3 million.
- All 10 of the most recent analyst ratings for RANI are Buy ratings with no Hold or Sell ratings, indicating unanimous positive sentiment among recent coverage.
Market Context
Rani Therapeutics Holdings, Inc. operates in the Healthcare sector. The stock currently trades at $0.79 with a market capitalization of $107.3M.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rani Therapeutics Holdings, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rani Therapeutics Holdings, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | Chardan Capital | Buy | N/A |
| May 20, 2026 | Canaccord Genuity | Buy | N/A |
| Apr 01, 2026 | Canaccord Genuity | Buy | N/A |
| Mar 27, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jan 09, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RANI Stock Page
Frequently Asked Questions
What does the Buy rating mean for RANI?
A rating of Buy from Chardan Capital reflects the analyst's outlook on Rani Therapeutics Holdings, Inc. (NASDAQ:RANI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RANI forecast page.